Guatemala vs Namibia: Average cost of drugs for extensively drug-resistant tuberculosis
Guatemala
11,910 constant 2022 US$
in 2024
Namibia
13,642 constant 2022 US$
in 2024
Guatemala rank
3rd
Namibia rank
2nd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Guatemala
- Namibia
How they compare
Namibia currently reports 13,642 constant 2022 US$ against 11,910 constant 2022 US$ in Guatemala, a difference of 1,732 constant 2022 US$.
That makes Namibia's figure about 1.1 times Guatemala's.
Across all 6 years both countries report, Namibia has been ahead every year.
Guatemala ranks 3rd and Namibia ranks 2nd of 56 countries.
Namibia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guatemala | Namibia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 11,075 constant 2022 US$ | 25,350 constant 2022 US$ | 14,275 constant 2022 US$ | Namibia |
| 2020s | 5,989 constant 2022 US$ | 18,909 constant 2022 US$ | 12,920 constant 2022 US$ | Namibia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Guatemala or Namibia?
- Namibia, at 13,642 constant 2022 US$ against 11,910 constant 2022 US$ in Guatemala as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Guatemala and Namibia?
- 1,732 constant 2022 US$, with Namibia ahead.
- How many years of comparable data are there for Guatemala and Namibia?
- 6 years are reported by both, from 2019 to 2024.
- How do Guatemala and Namibia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Guatemala ranks 3rd and Namibia ranks 2nd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.